The Taiwan Stock Exchange has announced that Dayan Biomedical International Co., Ltd. (7780) has submitted its application for stock listing on April 30, becoming the seventh domestic company to apply for listing this year. This wave of applications reflects the market's high expectations for the health food industry, drawing investor attention to Dayan Biomedical's future prospects.

According to the company's disclosures, the CEO is Chang Chia-Ming, and the paid-in capital is approximately NT$600 million, primarily engaged in the research and sales of health food products. Last year's financials were impressive, with a pre-tax net profit of NT$139 million and an after-tax earnings per share of NT$2.43, showcasing strong profitability.

In March, revenue reached NT$134 million, a year-on-year increase of over 203%, accumulating first-quarter revenue of NT$334 million, a year-on-year increase of 38.94%, setting a historical record for the same period.

The company focuses on fish oil as its core product, standing out in a red ocean market, and has successfully established a high-quality health brand in consumer minds, creating a differentiated advantage. So far this year, seven domestic companies have submitted listing applications, including Dayan Biomedical, demonstrating various industries' proactive stance towards positioning themselves in the capital market.

Experts point out that the health food market continues to thrive in the post-pandemic era, with Dayan Biomedical leveraging its fish oil product line's market share advantage and stable profitability record, likely to attract mid-to-long-term capital attention.